Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese

To study the origin of fat excess in the livers of morbidly obese (MO) individuals, we analysed lipids and lipases in both plasma and liver and genes involved in lipid transport, or related with, in that organ. Thirty-two MO patients were grouped according to the absence (healthy: DM - DL -) or pres...

Descripción completa

Detalles Bibliográficos
Autores: Pardina, Eva, Ferrer Costa, Roser|||0000-0002-8925-3172, Rossell, Joana|||0000-0003-1500-6379, Baena-Fustegueras, Juan Antonio, Lecube, Albert|||0000-0001-9684-0183, Fort, José Manuel, Caubet, Enric|||0000-0001-8867-4971, González López, Óscar|||0000-0002-2597-9257, Vilallonga, Ramón, Vargas Blasco, Víctor|||0000-0002-7190-6948, Balibrea Del Castillo, José María|||0000-0002-0764-7179, Peinado-Onsurbe, Julia
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:185845
Acceso en línea:https://ddd.uab.cat/record/185845
https://dx.doi.org/urn:doi:10.1016/j.bbacli.2015.12.002
Access Level:acceso abierto
Palabra clave:DM - DL -, "Healthy" obese patients, or patients without type 2 diabetes or dyslipidaemia
DM - DL +, Dyslipidemic obese patients
DM + DL +, Obese patients with type 2 diabetes and dyslipidaemia
HL, Hepatic lipase
VLDLr, Very-Low-Density Lipoprotein receptor
FAT/CD36, Fatty Acid Translocase or Cluster of Differentiation 36
LDLr, Low-Density Lipoprotein receptor
ApoB, Apolipoprotein B
PPARα, Peroxisome Proliferator-Activated Receptor alpha
PPARα, Peroxisome Proliferator-Activated Receptor gamma Coactivator 1-alpha
CYP7a1, Cholesterol 7 Alpha-Hydroxylase
HMGCR, 3-Hydroxy-3-Methylglutaryl-CoA Reductase
PAI1, Plasminogen Activator Inhibitor of Type 1
TNFα, Tumour Necrosis Factor-alpha
ATGL, Adipose Tissue Glycerol Lipase
SCARB1, Scavenger Receptor Class B, Member 1
CPT1a, Carnitine Palmitoyltransferase 1a
UCP2, Uncoupling Protein 2
INOS2, Inducible Nitric Oxide Synthase 2
ENOS3, Endothelial Nitric Oxide Synthase 3
IL6, Interleukin-6
TAGs, Triacylglycerides
NAFLD, Non-alcoholic fatty liver disease
IR, Insulin resistance
NASH, Non-alcoholic liver steatohepatitis
MO, Morbidly obese
BMI, Body Mass Index
DM, Type 2 diabetes mellitus
DL, Dyslipidaemia
RYGBP, Roux-en-Y gastric bypass
HTA, Hypertension
HOMA-IR, Homeostasis Model Assessment of Insulin Resistance
PLs, Phospholipids
TC, Total cholesterol
CLDL, Low-Density Lipoprotein Cholesterol
CHDL, High-Density Lipoprotein Cholesterol
NEFA, Non-esterified fatty acid
AST, Aspartate transaminase
ALT, Alanine transaminase
GGT, gamma-glutaryl transferase
CRP, C-reactive protein
KBs, Ketone bodies
ApoA1, Apolipoprotein A1
HSL, Hormone-sensitive lipase
QMs, Chylomicrons
SAT, Subcutaneous adipose tissue
VAT, Visceral adipose tissue
Steatosis
NAFLD
Liver
Lipases
Diabetes
Lipids
Descripción
Sumario:To study the origin of fat excess in the livers of morbidly obese (MO) individuals, we analysed lipids and lipases in both plasma and liver and genes involved in lipid transport, or related with, in that organ. Thirty-two MO patients were grouped according to the absence (healthy: DM - DL -) or presence of comorbidities (dyslipidemic: DM - DL +; or dyslipidemic with type 2 diabetes: DM + DL +) before and one year after gastric bypass. The livers of healthy, DL and DM patients contained more lipids (9.8, 9.5 and 13.7 times, respectively) than those of control subjects. The genes implicated in liver lipid uptake, including HL, LPL, VLDLr, and FAT / CD36, showed increased expression compared with the controls. The expression of genes involved in lipid-related processes outside of the liver, such as apoB, PPARα and PGC1α, CYP7a1 and HMGCR, was reduced in these patients compared with the controls. PAI1 and TNFα gene expression in the diabetic livers was increased compared with the other obese groups and control group. Increased steatosis and fibrosis were also noted in the MO individuals. Hepatic lipid parameters in MO patients change based on their comorbidities. The gene expression and lipid levels after bariatric surgery were less prominent in the diabetic patients. Lipid receptor overexpression could enable the liver to capture circulating lipids, thus favouring the steatosis typically observed in diabetic and dyslipidaemic MO individuals.